Annual General Meeting 2016 and Nomination Committee
The Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 28 April 2016 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.
Press releases
NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company. Effective today, Mikael Brönnegård will no longer serve as Chief Executive Off ...
NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication
CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Swe ...
NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015
Negative top-line result of phase III study and continued progress in other clinical projects
NeuroVive share upgraded on OTC market in US
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade ...
NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment el ...
NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes
Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...
NeuroVive Asia signs collaboration agreement with Sanofi for the development and commercialization of CicloMulsion® in South Korea
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi's local affiliate for the de ...
Sale of shares off the market following share exchange program
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that one of its insider registered persons has executed a limited share sale following completed share swaps from Maas ...
Topline result of Phase III study of CicloMulsion® in acute myocardial infarction expected this quarter
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, expects to announce the topline result of the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart ...
NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015
Capital raising characterizes NeuroVive ́s first quarter
NeuroVive announces prospectus regarding admission to trading of new shares
The prospectus regarding the admission to trading of newly issued shares in NeuroVive Pharmaceutical AB (publ) is now available on the company's website www.neurovive.se and in the company's offices, ...